COVID-19: Implications for Inflammatory Bowel Disease Patients
Implications of COVID-19 for inflammatory bowel disease patients with comments from Professor of Gastroenterology Dr. Giovanni Monteleone.
Eczema Treatment: Latest Research and Medications
Progress in the development of an effective and safe treatment for eczema has led to the study of multiple new medications.
Targeted Multiple Myeloma Treatment Melflufen Shows Efficacy for Difficult-to-Treat Triple-Class Refractory Disease
The targeted peptide-drug conjugate melflufen has shown efficacy for the treatment of triple-class refractory multiple myeloma.
Inovio Receives $5 Million Grant from Bill and Melinda Gates Foundation for COVID-19 Vaccine Program
Inovio Pharmaceuticals (Nasdaq: INO) has announced its recipientship of a $5 million grant from the Gates Foundation for their COVID-19 vaccine program.
Clinical Trial Demonstrates Enhancement of Immune Response to HIV by Gilead’s TLR7 Agonist Vesatolimod
Gilead (Nasdaq: GILD) has announced clinical trial results demonstrating the enhancement of the immune response to HIV by the TLR7 agonist Vesatolimod.
NuVasive Announces Publication Demonstrating Efficacy of Synthetic Putty in Lumbar Fusion
NuVasive, Inc. (Nasdaq: NUVA) has announced a recent publication demonstrating the efficacy of their synthetic bioactive putty in lumbar fusion.
Biocept Reports Publication Further Validating Cancer-Detecting Liquid Biopsy Platform
Biocept, Inc. (Nasdaq: BIOC) has announced a clinical research publication further validating its cancer-detecting liquid biopsy platform.
Moderna Completes Enrollment of Phase 2 Study Evaluating Cytomegalovirus Vaccine
Moderna, Inc. (Nasdaq: MRNA) has announced the completion of enrollment for a Phase 2 study evaluating its cytomegalovirus vaccine.
Gilead Initiates Two Phase 3 Trials of Remdesivir for Treatment of COVID-19
Gilead Sciences, Inc. (Nasdaq: GILD), has initiated two phase 3 clinical trials of the anti-viral agent remdesivir for the treatment of COVID-19.